Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19619754.
- Also identified by DOI 10.1016/j.jpeds.2009.01.058.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report the use of anti-interleukin-5 (mepolizumab) during an 18-month period in a pediatric hypereosinophilic syndrome. Infusions every 3 months allowed better control of hypereosinophilic syndrome flares and maintained blood eosinopenia with significantly less steroid use compared with all other therapies (prednisolone alone, interferon alpha, or imatinib mesylate).
Medical subject headings
- Antibodies, Monoclonal
- Hypereosinophilic Syndrome
- Interleukin-5